Pelthos Therapeutics Inc.(PTHS)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Pelthos Therapeutics Inc. (PTHS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTHS at 17.5/100 on a 32-signal composite quality model, placing it at rank #2,825 of 2,961 stocks — the bottom half of the AI-ranked universe. PTHS scores in the top quartile across institutional flow (84.2). Areas of concern include balance sheet strength (0.9) and profitability (5.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Pelthos Therapeutics Inc. reports quarterly revenue of $15.6M, net income of $-23.4M, free cash flow of $-7.7M. Top institutional holders of PTHS by reported 13-F value include AIGH Capital Management, Murchinson Ltd., Ikarian Capital, based on the most recent SEC filings. PTHS trades on the NYSE exchange and files with the SEC under CIK 1919246. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTHS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pelthos Therapeutics Inc. directly from SEC EDGAR.